蛋白丢失性肠病——心血管病诊治中被忽视的一隅

胡崧; 谭江山; 朱永建; 华潞

doi:10.13201/j.issn.1001-1439.2020.11.020

蛋白丢失性肠病——心血管病诊治中被忽视的一隅

- 中国医学科学院北京协和医学院国家心血管病中心阜外医院血栓性疾病诊治中心(北京, 100037)
基金项目:
中国医学科学院医学与健康科技创新工程经费资助(No:2017-I2M-3-003)

详细信息

通讯作者: 华潞,E-mail:ethannan@126.com

中图分类号: R541

收稿日期: 2020-06-13

Protein losing enteropathy-neglected in the diagnosis and treatment of cardiovascular diseases

- Thrombotic Disease Diagnosis and Treatment Center, National Center for Cardiovascular Diseases and Fuwai Hospital, CAMS and PUMC, Beijing, 100037, China

More Information

Corresponding author: HUA Lu, E-mail: ethannan@126.com

Received Date: 13 June 2020

摘要

摘要: 蛋白丢失性肠病(PLE)是由多种原发性疾病导致大量蛋白质从肠道丢失的临床综合征,最常继发于胃肠道疾病和心血管疾病。PLE的发生发展与心血管原发疾病密切相关,PLE目前在心血管领域整体认识度较低,未能及时诊断PLE,导致持续或难以纠正的低蛋白血症,原发疾病也可能随PLE的发展而逐渐复杂化,从而严重影响患者的生存质量和预后。本文详述了心血管疾病相关PLE的发病特点和机制,以及诊断和治疗,以期提高PLE的知晓率、诊断率和治疗率,改善患者的生活质量和预后。
- 蛋白丢失性肠病 /
- 心血管疾病 /
- 诊断 /
- 治疗
Abstract: Protein losing enteropathy(PLE) is a clinical syndrome in which a large amount of proteins is lost from the intestine due to a variety of primary diseases, most often secondary to gastrointestinal and cardiovascular disease. The occurrence and development of PLE are closely related to the primary cardiovascular diseases. The overall awareness of PLE in cardiovascular field is low currently. The failure to diagnose of PLE in time leads to persistent or uncorrectable hypoproteinemia. The primary disease may also be complicated by the progress of PLE, which seriously affects the life quality and prognosis of patients. This article details the characteristics and pathogenesis of cardiovascular disease-related PLE, as well as diagnosis and treatment, in order to raise the awareness, diagnosis rate and treatment rate of PLE, and improve the life quality and prognosis of patients.
- protein losing enteropathy /
- cardiovascular disease /
- diagnosis /
- treatment

HTML全文

参考文献(46)

[1]	Arques S.Human serum albumin in cardiovascular diseases[J].Eur J Intern Med,2018,52:8-12.
[2]	Akirov A,Masri-Iraqi H,Atamna A,et al.Low albumin levels are associated with mortality risk in hospitalized patients[J].Am J Med,2017,130(12):1465.e11-1465.e19.
[3]	Umar SB,DiBaise JK.Protein-losing enteropathy:case illustrations and clinical review[J].Am J Gastroenterol,2010,105(1):43-49.
[4]	Kreisel W,Ruf G,Salm R,et al.Protein-losing pseudomembranous colitis with cap polyposis-like features[J].World J Gastroenterol,2017,23(16):3003-3010.
[5]	Braamskamp MJ,Dolman KM,Tabbers MM.Clinical practice.Protein-losing enteropathy in children[J].Eur J Pediatr,2010,169(10):1179-1185.
[6]	Stephen J,Vilboux T,Haberman Y,et al.Congenital protein losing enteropathy:an inborn error of lipid metabolism due to DGAT1 mutations[J].Eur J Hum Genet,2016,24(9):1268-1273.
[7]	Kurolap A,Eshach-Adiv O,Gonzaga-Jauregui C,et al.Establishing the role of PLVAP in protein-losing enteropathy:a homozygous missense variant leads to an attenuated phenotype[J].J Med Genet,2018,55(11):779-784.
[8]	Ozen A,Comrie WA,Ardy RC,et al.CD55 deficiency,early-onset protein-losing enteropathy,and thrombosis[J].N Engl J Med,2017,377(1):52-61.
[9]	Davidson JD,Waldmann TA,Goodman DS,et al.Protein-losing gastroenteropathy in congestive heart-failure[J].Lancet,1961,1(7183):899-902.
[10]	Schleiger A,Ovroutski S,Peters B,et al.Treatment strategies for protein-losing enteropathy in Fontan-palliated patients[J].Cardiol Young,2020,30(5):698-709.
[11]	Rychik J,Atz AM,Celermajer DS,et al.Evaluation and management of the child and adult with fontan circulation:a scientific statement from the American Heart Association[J].Circulation,2019:CIR0000000000000696.
[12]	Al Balushi A,Mackie AS.Protein-losing enteropathy following fontan palliation[J].Can J Cardiol,2019,35(12):1857-1860.
[13]	Johnson JN,Driscoll DJ,O'Leary PW.Protein-losing enteropathy and the Fontan operation[J].Nutr Clin Pract,2012,27(3):375-384.
[14]	Mertens L,Hagler DJ,Sauer U,et al.Protein-losing enteropathy after the Fontan operation:an international multicenter study.PLE study group[J].J Thorac Cardiovasc Surg,1998,115(5):1063-1073.
[15]	Feldt RH,Driscoll DJ,Offord KP,et al.Protein-losing enteropathy after the Fontan operation[J].J Thorac Cardiovasc Surg,1996,112(3):672-680.
[16]	Silvilairat S,Cabalka AK,Cetta F,et al.Protein-losing enteropathy after the Fontan operation:associations and predictors of clinical outcome[J].Congenit Heart Dis,2008,3(4):262-268.
[17]	Ohuchi H,Yasuda K,Miyazaki A,et al.Haemodynamic characteristics before and after the onset of protein losing enteropathy in patients after the Fontan operation[J].Eur J Cardiothorac Surg,2013,43(3):e49-57.
[18]	Breatnach CR,Cleary A,Prendiville T,et al.Prevalence of subclinical enteric alpha-1-antitrypsin loss in children with univentricular circulation following total cavopulmonary connection[J].Pediatr Cardiol,2018,39(1):33-37.
[19]	Meijers BK,Schalla S,Eerens F,et al.Protein-losing enteropathy in association with constrictive pericarditis[J].Int J Cardiovasc Imaging,2006,22(3-4):389-392.
[20]	Gursu HA,Varan B,Erdogan I.Use of oral budesonide in the management of protein-losing enteropathy due to restrictive cardiomyopathy[J].Cardiol Young,2014,24(4):764-746.
[21]	Lee LC,Wong R,Raju GC,et al.Protein-losing enteropathy post-valvular surgery with severe tricuspid regurgitation in Subutex-related endocarditis[J].Singapore Med J,2009,50(4):e124-126.
[22]	Melenovsky V,Kubanek M,Kacer P.Protein-losing enteropathy in an adult with non-ischaemic cardiomyopathy:complete reversal by heart transplantation[J].ESC Heart Fail,2018,5(5):842-845.
[23]	Ohira H,Tsujino I,Sakaue S,et al.Recovery of protein-losing enteropathy after living-donor lobar lung transplantation in primary pulmonary hypertension[J].J Heart Lung Transplant,2006,25(4):486-488.
[24]	Elli L,Topa M,Rimondi A.Protein-losing enteropathy[J].Curr Opin Gastroenterol,2020,36(3):238-244.
[25]	Desai AP,Guvenc BH,Carachi R.Evidence for medium chain triglycerides in the treatment of primary intestinal lymphangiectasia[J].Eur J Pediatr Surg,2009,19(4):241-245.
[26]	John AS,Johnson JA,Khan M,et al.Clinical outcomes and improved survival in patients with protein-losing enteropathy after the Fontan operation[J].J Am Coll Cardiol,2014,64(1):54-62.
[27]	贾静静,赵劲东,董平栓,等.补充维生素D对心力衰竭患者临床作用的Meta分析[J].临床心血管病杂志,2018,34(2):136-141.
[28]	Bejiqi R,Retkoceri R,Zeka N,et al.Treatment of children with protein-losing enteropathy after fontan and other complex congenital heart disease procedures in condition with limited human and technical resources[J].Mater Sociomed,2014,26(1):39-42.
[29]	赵跃华,孟小敏,李向欣,等.心力衰竭诊断与药物治疗的研究进展[J].临床心血管病杂志,2020,36(4):382-386.
[30]	廖玉华,杨杰孚,张健,等.舒张性心力衰竭诊断和治疗专家共识[J].临床心血管病杂志,2020,36(1):1-10.
[31]	Thacker D,Patel A,Dodds K,et al.Use of oral budesonide in the management of protein-losing enteropathy after the Fontan operation[J].Ann Thorac Surg,2010,89(3):837-842.
[32]	Therrien J,Webb GD,Gatzoulis MA.Reversal of protein losing enteropathy with prednisone in adults with modified fontan operations:long term palliation or bridge to cardiac transplantation?[J].Heart,1999,82(2):241-243.
[33]	Schumacher KR,Cools M,Goldstein BH,et al.Oral budesonide treatment for protein-losing enteropathy in Fontan-palliated patients[J].Pediatr Cardiol,2011,32(7):966-971.
[34]	Donnelly JP,Rosenthal A,Castle VP,et al.Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation[J].J Pediatr,1997,130(3):474-478.
[35]	Kuroiwa G,Takayama T,Sato Y,et al.Primary intestinal lymphangiectasia successfully treated with octreotide[J].J Gastroenterol,2001,36(2):129-132.
[36]	John AS,Phillips SD,Driscoll DJ,et al.The use of octreotide to successfully treat protein-losing enteropathy following the Fontan operation[J].Congenit Heart Dis,2011,6(6):653-656.
[37]	Hofmann AF.Increased deoxycholic acid absorption and gall stones in acromegalic patients treated with octreotide:more evidence for a connection between slow transit constipation and gall stones[J].Gut,2005,54(5):575-578.
[38]	Meadows J,Jenkins K.Protein-losing enteropathy:integrating a new disease paradigm into recommendations for prevention and treatment[J].Cardiol Young,2011,21(4):363-377.
[39]	Vyas H,Driscoll DJ,Cabalka AK,et al.Results of transcatheter Fontan fenestration to treat protein losing enteropathy[J].Catheter Cardiovasc Interv,2007,69(4):584-589.
[40]	Latson L.Once more unto the breach:a new treatment paradigm for protein-losing enteropathy[J].J Am Coll Cardiol,2017,69(24):2938-2940.
[41]	Itkin M,Piccoli DA,Nadolski G,et al.Protein-losing enteropathy in patients with congenital heart disease[J].J Am Coll Cardiol,2017,69(24):2929-2937.
[42]	Müller C,Globits S,Glogar D,et al.Constrictive pericarditis without typical haemodynamic changes as a cause of oedema formation due to protein-losing enteropathy[J].Eur Heart J,1991,12(10):1140-1143.
[43]	Moriyama H,Kohno T,Nishiyama T,et al.Constrictive pericarditis and protein-losing enteropathy:is extremely severe hypoalbuminemia reversible by pericardiectomy?[J].Circ Heart Fail,2016,9(12):110-122.
[44]	Wilkinson P,Pinto B,Senior JR.Reversible protein-losing enteropathy with intestinal lymphangiectasia secondary to chronic constrictive pericarditis[J].N Engl J Med,1965,273(22):1178-1181.
[45]	Hiew C,Collins N,Foy A,et al.Successful surgical treatment of protein-losing enteropathy complicating rheumatic tricuspid regurgitation[J].Heart Lung Circ,2008,17(1):73-75.
[46]	Yamanaka O,Ozaki H,Kanoh T,et al.A case of isolated tricuspid regurgitation associated with protein-losing gastroenteropathy[J].Kokyu To Junkan,1989,37(3):351-356.